Magazine survey recognized bioMérieux based on customer support, reliable instrumentation, and rapid response.
Asia
Europe, Middle East, Africa
North America
Laboratory Customers Name bioMérieux "Top of Class" for Microbiology
17 December, 2008
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
14 December, 2008
Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients.
bioMérieux Acquires Culture Media Specialist PML Microbiologicals; bioMérieux's Recurring Sales Will be Boosted by Expanded Reagent Range
08 December, 2008
bioMérieux, a world leader in the field of in vitro diagnostics has acquired PML Microbiologicals Inc., a leading provider of culture media and microbiological products in North America for both clinical and industrial applications. This privately held American in vitro diagnostics company has manufacturing and marketing teams based in Portland, Oregon and Toronto, Canada.
bioMérieux Business Review for the Nine Months Ended September 20, 2008
28 October, 2008
bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008.
bioMérieux Receives Prestigious Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology - bioMérieux Recognized for Outstanding Vision in U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market
14 October, 2008
bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology.
U.S. Lab Professionals Indicate Urgency for Automated Solutions
09 October, 2008
Survey conducted at AACC conference stresses need for laboratory automation to offset Staff Shortages and improve Turn Around Time for Tests.
bioMérieux to Break Ground on Eco-Friendly Facility on the Hazelwood Campus
06 October, 2008
October 6 groundbreaking ceremony expands company’s presence in the U.S.
bioMérieux to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
25 September, 2008
Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone.
bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx
11 September, 2008
bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
First-Half 2008 Financial Report
08 September, 2008
bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008.